Evidence map›Paper›PMID 34326847›Full record

ArticleFrontiers in immunology2021

Allo-Specific Humoral Responses: New Methods for Screening Donor-Specific Antibody and Characterization of HLA-Specific Memory B Cells.

Shengli Song, Miriam Manook, Jean Kwun, Annette M Jackson, Stuart J Knechtle, Garnett Kelsoe

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. A novel immunoglobulin G- and immunoglobulin cleaving enzyme MG (IceMG), for antibody-mediated rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shengli SongDepartment of Immunology, Duke University School of Medicine, Durham, NC, United States.
Miriam ManookDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Jean KwunDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Annette M JacksonDepartment of Immunology, Duke University School of Medicine, Durham, NC, United States.
Stuart J KnechtleDepartment of Surgery, Duke University School of Medicine, Durham, NC, United States.
Garnett KelsoeDepartment of Immunology, Duke University School of Medicine, Durham, NC, United States.
Duke University · US

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
The Risks and Opportunities of Homeostatic RepopulationU19AI131471 · NIAID · DUKE UNIVERSITY · PI Jean Kwun · 2017 to 2026
$30.4M
Immunity to novel T/F SHIVs: variability in the co-evolution of virus and host immunityR01AI128832 · NIAID · DUKE UNIVERSITY · PI KELSOE, GARNETT H · 2017 to 2021
$5.4M
NIAID NIH HHS R01 AI128832NIAID NIH HHS U19 AI131471NIAID NIH HHS UM1 AI109565
6 · The paper itself

Abstract

Antibody-mediated allograft rejection (AMR) causes more kidney transplant failure than any other single cause. AMR is mediated by antibodies recognizing antigens expressed by the graft, and antibodies generated against major histocompatibility complex (MHC) mismatches are especially problematic. Most research directed towards the management of clinical AMR has focused on identifying and characterizing circulating donor-specific HLA antibody (DSA) and optimizing therapies that reduce B-cell activation and/or block antibody secretion by inhibiting plasmacyte survival. Here we describe a novel set of reagents and techniques to allow more specific measurements of MHC sensitization across different animal transplant models. Additionally, we have used these approaches to isolate and clone individual HLA-specific B cells from patients sensitized by pregnancy or transplantation. We have identified and characterized the phenotypes of individual HLA-specific B cells, determined the V(D)J rearrangements of their paired H and L chains, and generated recombinant antibodies to determine affinity and specificity. Knowledge of the BCR genes of individual HLA-specific B cells will allow identification of clonally related B cells by high-throughput sequence analysis of peripheral blood mononuclear cells and permit us to re-construct the origins of HLA-specific B cells and follow their somatic evolution by mutation and selection.

Indexed as

Immunologic MemoryAnimalsAntibody Specificitybeta 2-MicroglobulinB-Lymphocyte SubsetsCell LineCells, CulturedClonal EvolutionClone CellsFemaleGene Rearrangement, B-LymphocyteGenes, ReporterGraft RejectionHistocompatibility AntigensHLA AntigensHumansbeta 2-MicroglobulinHistocompatibility AntigensHLA AntigensImmunoglobulin GIndicators and ReagentsIsoantibodiesRNA, Guide, CRISPR-Cas Systemsantibody mediated rejection (AMR)B celldonor specific antibody (DSA)sensitizationtransplantation

Identifiers

PMID34326847
PMCPMC8313870
OpenAlexW3178649094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.